These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35213415)

  • 1. Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.
    Hotz MJ; O'Halloran EA; Hill MV; Hayden K; Zaladonis AG; Deng M; Olszanski AJ; Reddy SS; Wu H; Luo B; Farma JM
    Melanoma Res; 2022 Apr; 32(2):112-119. PubMed ID: 35213415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
    Eckardt J; Schroeder C; Martus P; Armeanu-Ebinger S; Kelemen O; Gschwind A; Bonzheim I; Eigentler T; Amaral T; Ossowski S; Rieß O; Flatz L; Garbe C; Forschner A
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):833-840. PubMed ID: 35192052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
    Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
    Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutation burden-assisted risk stratification for papillary thyroid cancer.
    Chen Z; Wang W; Xu J; Song Y; Zhu H; Ma T; Ge M; Guan H
    Endocrine; 2022 Nov; 78(2):296-305. PubMed ID: 35962256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF
    Robert C; Lewis KD; Gutzmer R; Stroyakovskiy D; Gogas H; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Caro I; Forbes H; Shah K; Yan Y; Li H; McArthur GA; Ascierto PA
    Ann Oncol; 2022 May; 33(5):544-555. PubMed ID: 35131452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Next-Generation Sequencing-Based Panel to
    Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
    Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
    Aoude LG; Bonazzi VF; Brosda S; Patel K; Koufariotis LT; Oey H; Nones K; Wood S; Pearson JV; Lonie JM; Arneil M; Atkinson V; Smithers BM; Waddell N; Barbour AP
    Sci Rep; 2020 Oct; 10(1):17687. PubMed ID: 33077847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.
    Parisi R; Patel RR; Rood G; Bowden A; Turco G; Korones DN; Andolina JR; Comito M; Barth M; Weintraub L
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30139. PubMed ID: 36573296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
    Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA
    Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRAS mutation status is an independent prognostic factor in metastatic melanoma.
    Jakob JA; Bassett RL; Ng CS; Curry JL; Joseph RW; Alvarado GC; Rohlfs ML; Richard J; Gershenwald JE; Kim KB; Lazar AJ; Hwu P; Davies MA
    Cancer; 2012 Aug; 118(16):4014-23. PubMed ID: 22180178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
    Quan VL; Zhang B; Zhang Y; Mohan LS; Shi K; Wagner A; Kruse L; Taxter T; Beaubier N; White K; Zou L; Gerami P
    J Invest Dermatol; 2020 Aug; 140(8):1599-1608. PubMed ID: 32004563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.